The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma

PURPOSE: The aim of this study was to investigate the efficacy of various epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) plus bevacizumab in advanced EGFR-mutant lung adenocarcinoma patients. MATERIALS AND METHODS: From August 2016 to October 2020, we enrolled advanced lun...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yen-Hsiang, Hsu, Kuo-Hsuan, Chin, Chun-Shih, Tseng, Jeng-Sen, Yang, Tsung-Ying, Chen, Kun-Chieh, Su, Kang-Yi, Yu, Sung-Liang, Chen, Jeremy J.W., Chang, Gee-Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016311/
https://www.ncbi.nlm.nih.gov/pubmed/34352999
http://dx.doi.org/10.4143/crt.2021.671

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016311/
https://www.ncbi.nlm.nih.gov/pubmed/34352999
http://dx.doi.org/10.4143/crt.2021.671

Ejemplares similares